ReviewScience China. Life sciences2026
Unveiling the enigma of anxiety disorders and depression: from pathogenesis to treatment.
Review in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanisms of interaction between type 2 diabetes and psychological disorders and therapeutic interventions: a narrative review.Frontiers in medicine · 2026Review
- Chronic administration of isotretinoin induces depressive- and anxiety-like behaviors by altering the neuroactive ligand-receptor interaction pathway in adolescent mice.Translational psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anxiety disorders and depression are among the most prevalent and disabling mental health conditions globally, profoundly impairing both individual well-being and societal functioning. Recent research has elucidated key neurobiological underpinnings of these disorders, including neurotransmitter imbalances, dysregulation of stress response systems, and dysfunctions within neural circuits governing emotion regulation. These insights offer significant potential for refining diagnostic approaches, enhancing prevention strategies, and improving therapeutic interventions. While conventional pharmacotherapy and psychotherapy have shown efficacy in managing anxiety and depression, their limitations underscore the urgent need to deepen understanding of the underlying pathophysiological mechanisms and to develop more targeted and personalized therapies. This review synthesizes recent progress in delineating the neurobiological, genetic, and psychosocial mechanisms contributing to anxiety and depression. It further evaluates current therapeutic strategies, encompassing both pharmacological and non-pharmacological interventions, to offer an integrated perspective on treatment paradigms. By bridging foundational scientific research with clinical applications, this review aims to inform future investigations and facilitate the development of more effective, individualized therapeutic approaches to improve patient outcomes.
Indexed as
Identifiers
40900421What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.